Last reviewed · How we verify
Oshadi D
At a glance
| Generic name | Oshadi D |
|---|---|
| Sponsor | Oshadi Drug Administration |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment (PHASE1, PHASE2)
- Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer (PHASE2)
- Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients (PHASE2)
- Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study (PHASE2)
- Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment (PHASE1)
- Evaluation of the Influence of Food Regimen on Oshadi D Absorption (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oshadi D CI brief — competitive landscape report
- Oshadi D updates RSS · CI watch RSS
- Oshadi Drug Administration portfolio CI